NewGenIvf Group Limited (NASDAQ:NIVF) Sees Large Decrease in Short Interest

NewGenIvf Group Limited (NASDAQ:NIVF) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 22,408 shares, a decline of 52.3% from the March 31st total of 46,988 shares. Currently, 13.3% of the shares of the company are short sold. Based on an average trading volume of 16,760 shares, the days-to-cover ratio is currently 1.3 days.

NewGenIvf Group Stock Down 5.1%

Shares of NASDAQ NIVF traded down $0.10 during mid-day trading on Tuesday, hitting $1.86. The company had a trading volume of 16,125 shares, compared to its average volume of 150,184. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98. NewGenIvf Group has a 1 year low of $1.52 and a 1 year high of $1,839.00. The stock’s 50-day moving average price is $2.32 and its 200-day moving average price is $17.09.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NewGenIvf Group has a consensus rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.